Clinical utility of a comprehensive genomic profiling test for patient with advanced biliary tract cancer
International Journal of Clinical Oncology · 2024
DOI: 10.1007/s10147-024-02616-x ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Clinical Oncology, 2024. Verfasst von Hiroki Inada und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto University, 1-1-1, Honjo, Chuo-Ku, Kumamoto, 8…. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development, JSPS Grants-in-Aid for Scientific Research, Kumamoto University Hospital Young Researcher Activation Project.
Abstract (Originalsprache)
BACKGROUND: Biliary tract cancer (BTC) comprises a heterogeneous group of malignancies with poor prognosis because of the limited treatment options. With the recent advances of next generation sequencing technologies, comprehensive genomic profiling (CGP) tests have been widely introduced into daily clinical practice. PATIENTS AND METHODS: We performed a retrospective, multicenter, observation cohort study. The genomic and clinical data of 85 BTC patients, who underwent CGP testing from August 2021 to September 2023, were analyzed. RESULTS: There were 62 (73%) cases in which treatment recommendations were raised during expert meetings, including 34 intrahepatic cholangiocarcinoma (ICC), 20 extrahepatic cholangiocarcinoma (ECC) and 8 gall bladder carcinoma (GBC). The drug accessibility rate of the BTC patients was 15.3% (13 cases): ten ICCs, two ECCs, and one GBC. Five ICC patients (three male and two female) with the FGFR2 fusion gene were treated with pemigatinib. Those patients who received a genomically matched therapy had significantly longer median overall survival than those patients who not received. (n = 13; not reached [95% CI not reached-not reached] vs n = 72; 8.6 months [95% CI 6.6-10.0]; hazard ratio 0.24 [95% CI 0.12-0.49], p = 0.013). The median observation period of pemigatinib treatment was 15.4 months (range 10.1-27.4). The responses were classified as PR in three patients, SD in one patient and PD in one patient. The median progression free survival is 9.0 months. No patient had grade 3/4 AEs requiring discontinuation of the treatment. CONCLUSION: The drug accessibility rate of ICC is high and pemigatinib is effective and well-tolerated in ICC patients harboring FGFR2 gene fusions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto University, 1-1-1, Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan.
- Cancer Genome Center, Kumamoto University Hospital, Kumamoto, Japan.
- Department of Molecular Laboratory Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
- Division of Integrative Medical Oncology, Saiseikai Kumamoto Hospital, Kumamoto, Japan.
- Department of Diagnostic Pathology, Kumamoto University Hospital, Kumamoto, Japan.
- Department of Gastroenterology, Kumamoto Kenhoku Hospital, Kumamoto, Japan.
Förderung
- Japan Agency for Medical Research and Development
- JSPS Grants-in-Aid for Scientific Research
- Kumamoto University Hospital Young Researcher Activation Project
Zitieren
APA
Inada, H., Miyamoto, H., Shinriki, S., Oda, H., Narahara, S., Yoshinari, M., Nagaoka, K., Yoshii, D., Fukubayashi, K., Hayashi, H., Baba, H., Nosaka, K., & Tanaka, Y. (2024). Clinical utility of a comprehensive genomic profiling test for patient with advanced biliary tract cancer. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02616-x
Vancouver
Inada H, Miyamoto H, Shinriki S, Oda H, Narahara S, Yoshinari M, et al. Clinical utility of a comprehensive genomic profiling test for patient with advanced biliary tract cancer. International Journal of Clinical Oncology. 2024. doi:10.1007/s10147-024-02616-x
BibTeX
@article{Inada2024,
author = {Inada, Hiroki and Miyamoto, Hideaki and Shinriki, Satoru and Oda, Hisanobu and Narahara, Satoshi and Yoshinari, Motohiro and Nagaoka, Katsuya and Yoshii, Daiki and Fukubayashi, Kotaro and Hayashi, Hiromitsu and Baba, Hideo and Nosaka, Kisato and Tanaka, Yasuhito},
title = {Clinical utility of a comprehensive genomic profiling test for patient with advanced biliary tract cancer},
journal = {International Journal of Clinical Oncology},
year = {2024},
doi = {10.1007/s10147-024-02616-x}
}
EUVIMED